Moskowitz AJ, Shah G, Schoder H, Ganesan N, et al. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol 2021 Jun 25:JCO2101056. doi: 10.1200/JCO.21.01056.
PMID: 34170745